Overall survival at 5 years of follow-up in a phase III trial comparing ipilimumab 10 mg/kg with 3 mg/kg in patients with advanced melanoma - Archive ouverte HAL Access content directly
Journal Articles Journal for Immunotherapy of Cancer Year : 2020

Overall survival at 5 years of follow-up in a phase III trial comparing ipilimumab 10 mg/kg with 3 mg/kg in patients with advanced melanoma

(1) , (2) , (3) , (4, 5, 6) , (7) , (8) , (9, 10) , (11, 12) , (13) , (14) , (15) , (16, 17) , , (18) , (19) , (20, 21) , (22) , (23) , (24, 25) , (26) , (27) , (28) , (29) , (30) , (31) , (32) , (33) , (34) , (34) , (35)
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
Omid Hamid
  • Function : Author

Abstract

Background: We have previously reported significantly longer overall survival (OS) with ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with advanced melanoma, with higher incidences of adverse events (AEs) at 10 mg/kg. This follow-up analysis reports a 5-year update of OS and safety. Methods: This randomized, multicenter, double-blind, phase III trial included patients with untreated or previously treated unresectable stage III or IV melanoma. Patients were randomly assigned (1:1) to ipilimumab 10 mg/kg or 3 mg/kg every 3 weeks for 4 doses. The primary end point was OS. Results: At a minimum follow-up of 61 months, median OS was 15.7 months (95% CI 11.6 to 17.8) at 10 mg/kg and 11.5 months (95% CI 9.9 to 13.3) at 3 mg/kg (HR 0.84, 95% CI 0.71 to 0.99; p=0.04). In a subgroup analysis, median OS of patients with asymptomatic brain metastasis was 7.0 months (95% CI 4.0 to 12.8) in the 10 mg/kg group and 5.7 months (95% CI 4.2 to 7.0) in the 3 mg/kg group. In patients with wild-type or mutant BRAF tumors, median OS was 13.8 months (95% CI 10.2 to 17.0) and 33.2 months (95% CI 19.4 to 45.2) in the 10 mg/kg group, and 11.2 months (95% CI 9.2 to 13.8) and 19.7 months (95% CI 11.6 to 25.3) in the 3 mg/kg group, respectively. The incidence of grade 3/4 treatment-related AEs was 36% in the 10 mg/kg group vs 20% in the 3 mg/kg group, and deaths due to treatment-related AEs occurred in four (1%) and two patients (1%), respectively. Conclusions: This 61-month follow-up of a phase III trial showed sustained long-term survival in patients with advanced melanoma who started metastatic treatment with ipilimumab monotherapy, and confirmed the significant benefit for those who received ipilimumab 10 mg/kg vs 3 mg/kg. These results suggest the emergence of a plateau in the OS curve, consistent with previous ipilimumab studies.
Fichier principal
Vignette du fichier
e000391.full.pdf (1.93 Mo) Télécharger le fichier
Origin : Publication funded by an institution

Dates and versions

inserm-03709901 , version 1 (30-06-2022)

Identifiers

Cite

Paolo Antonio Ascierto, Michelle del Vecchio, Andrzej Mackiewicz, Caroline Robert, Vanna Chiarion-Sileni, et al.. Overall survival at 5 years of follow-up in a phase III trial comparing ipilimumab 10 mg/kg with 3 mg/kg in patients with advanced melanoma. Journal for Immunotherapy of Cancer, 2020, 8 (1), pp.e000391. ⟨10.1136/jitc-2019-000391⟩. ⟨inserm-03709901⟩
7 View
8 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More